Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma by Massari, Francesco et al.
 
 
This is the author's manuscript of the article published in final edited form as: 
 
Massari, F., Ciccarese, C., Santoni, M., Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Cheng, L. (2015). 
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer 
Therapy, 15(12), 1367–1369. http://doi.org/10.1586/14737140.2015.1110488  
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma 
Francesco Massari, Chiara Ciccarese, Matteo Santoni, Antonio Lopez-Beltran, Marina Scarpelli, 
Rodolfo Montironi & Liang Cheng 
 
Abstract 
Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial 
growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape 
VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy 
in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase 
inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma 
and on the ongoing trials of emerging agents targeting this axis. 
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Introduction 
Angiogenesis is the hallmark of kidney cancer development and progression. Therefore, the 
crucial drivers of metastatic renal cell carcinoma (mRCC) – VEGF and mTOR signaling 
pathways – represent fundamental targets of the current approved therapies. Certainly, VEGF 
receptor-tyrosine kinase inhibitors (VEGFR-TKIs) (sunitinib, sorafenib, pazopanib and axitinib) 
and mTOR-inhibitors (everolimus and temsirolimus) have dramatically revolutionized the 
treatment algorithm and the prognosis of mRCC patients [1]; however, almost all patients 
invariably develop tumor progression through primarily (intrinsic) or acquired resistance 
mechanisms.[2] 
Determinants of VEGF-targeted therapies response and the molecular bases underlying the 
antiangiogenic escape are far from being entirely understood.[3,4] This presents a substantial 
barrier to the achievement of complete durable responses to anticancer treatments. 
The inhibition of the major regulator of angiogenesis, VEGF, results in vascular regression and 
consequent tumor response to treatment. However, the creation of intratumoral hypoxic regions 
triggers the hyperexpression of other proangiogenic factors responsible for mediating 
angiogenesis reactivation and therefore tumor treatment’s resistance and progression. Several 
growth factors (PIGF, FGF, angiopoietin-1, IL8, Ephrin-A1), which are upregulated in the tumor 
microenvironment during VEGFR2-blocking treatments, may stimulate tumor angiogenesis to 
overcome acquired resistance to VEGFR inhibition.[5–7] In particular, activation of the 
proangiogenic fibroblast growth factor (FGF) pathway seems to play a key role in driving 
VEGF-independent tumor angiogenesis as a compensatory mechanism to elude VEGF-targetedz 
therapies.[7] 
FGF/fibroblast growth factor receptor (FGFR) signaling promotes vascularization (vessel 
assembly, sprouting and branching), lymphangiogenesis and cellular growth in several human 
malignancies,[8–10] including RCC.[11] Interestingly, increased basic-FGF plasma 
concentrations correlate with high tumor grade and stage,[12] metastatic spreading [13] and poor 
prognosis [14] in kidney cancer patients. Moreover, FGF serum levels significantly increase in 
mRCC patients with disease progression while receiving sunitinib therapy, supporting the 
potential FGF-pathway role as a potent mediator of endothelial cell resistance to VEGFR 
inhibitors.[15,16] 
Emerging FGF/FGFR inhibitors 
Targeting antiangiogenic escape via FGF-pathway blockade is a promising strategy after 
progression on VEGF-inhibitors therapy. Several molecules capable of simultaneously inhibiting 
both VEGF and FGF have been developed. 
Dovitinib, a TKI that targets FGFR, PDGRF and VEGFR,[17] failed in demonstrating a 
progression-free survival (PFS) and overall survival advantage over sorafenib in the third-line 
setting after progression to VEGFR and mTOR inhibitors, not corroborating the strong 
preclinical rational of targeting the FGF pathway critical for antiangiogenic escape.[18] The 
main criticism of this phase 3 study (the GOLD trial) lies in the inappropriate timing of FGF 
inhibition (immediately after failure of an mTOR inhibitor).[19] During mTOR inhibition 
treatment, in fact, cancer cells could restore a VEGF-driven angiogenesis (rather than FGF), 
given the temporary effects of VEGF-inhibitor resistance.[20] The wrong timing, and probably 
not the wrong target, compromised the clinical approval of dovitinib, at least at the moment. A 
phase 2 study (DILIGENCE-1) is ongoing, evaluating the first-line activity of dovitinib in RCC, 
with a preplanned exploratory tumor gene status analysis aimed at identifying possible ways in 
which the tumor becomes resistant to dovitinib (NCT01791387). 
Indirect evidence of greater efficacy by blocking FGFR immediately after the occurrence of 
VEGFR-TKIs resistance comes from the impressive results of another FGFR inhibitor, 
lenvatinib. Lenvatinib is a potent oral TKI of VEGF- and FGF-driven angiogenesis, which 
showed an acceptable safety profile and an encouraging antitumor activity in preclinical models 
[21] and in patients with multiple solid tumors, including mRCC in phase 1 studies.[22,23] A 
phase 1b clinical trial of lenvatinib plus everolimus in mRCC revealed a manageable safety 
profile with no unexpected toxic manifestations, and a promising antitumor activity,[24] 
highlighting the solid rational of concurrently blocking critical signaling pathways activated in 
RCC–VEGF, FGF and mTOR pathways.[25] At the 2015 ASCO Annual Meeting Motzer and 
colleagues presented the impressive results of a randomized phase 2 study comparing lenvatinib 
± everolimus, versus everolimus alone in 153 mRCC patients who progressed on one prior 
VEGF-targeted therapy.[26] Lenvatinib improved response rate (highest response rate and 
duration with combination treatment than with lenvatinib alone) and PFS over everolimus both 
alone and in combination with everolimus (mPFS 5.5 vs 7.4 vs 14.6 months), while a significant 
survival benefit was observed only with the combination regimen (Hazard ratio [HR]: 0.51; 95% 
CI: 0.30–0.88; p = 0.024), at the price of greater toxicity. A phase 3 randomized trial of the 
combination in mRCC is planned to confirm these promising results. 
Several novel emerging TKI molecules that recognize FGFR as a target are currently under study 
for the treatment of RCC, with conflicting data. Among them, brivanib, a dual VEGFR-2 and 
FGFR-1 TKI, demonstrated promising antiangiogenic and antitumor activity with manageable 
toxicity in advanced solid tumor patients.[27] We are awaiting the results of a phase 2, open-
label trial conducted to assess the activity of brivanib in refractory mRCC patients 
(NCT01253668). 
As for regorafenib (BAY 73-4506), a multikinase inhibitor targeting VEGFR, c-kit, RET, FGFR, 
platelet-derived growth factor receptor (PDGFR), RAF and p38MAPK, it was tested in a single-
arm phase 2 trial (NCT00664326) conducted in 49 previously untreated advanced RCC patients, 
showing antitumor activity as first-line treatment (27% PR and 42% SD), with a significant 
toxicity (35% of drug-related serious adverse events).[28] 
In addition XL999, a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, 
FGFR, FLT-3, and Src, was evaluated in a phase 2 study enrolling mRCC patients after failure of 
one anti-VEGF therapy (NCT00277316). The study was stopped due to the cardiac toxicities, 
impeding further development of this drug. 
Furthermore, a phase 1 study (NCT02275910) is recruiting subjects with advanced solid tumors 
for testing the safety and tolerability of E7090, especially in patients with malignancies 
characterized by genetic abnormalities in FGF/FGFR pathway. On the other hand, the small 
molecule TKI PD173074, a potent reversible inhibitor of FGFR tyrosine kinase activity,[29] 
seems to inhibit FGF2-mediated resistance to sunitinib in preclinical models.[16] 
Conclusion 
A multidisciplinary integrated approach is needed for deeper understanding of tumor biology of 
RCC. An increasing number of molecules are emerging in the treatment landscape of this tumor. 
Recently, the multikinase inhibitor, cabozantinib, and the anti-PD1, nivolumab, join the list of 
active therapies, demonstrating significant overall survival benefit.[30,31] A major issue which 
remains is the selection of the best drug available for each specific patient. Only an in-depth 
study of the carcinogenesis biological bases and of the mechanisms underlying treatment 
resistance could enable radically changes of the cancer patient’s prognosis with the development 
of true personalized therapy. 
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